What Comes After Ozempic? Next-Gen Weight Loss Drugs - Amycretin and the Amylin Revolution

What Comes After Ozempic? Next-Gen Weight Loss Drugs - Explore the future of medicine with Dr. Ben Synth

Join Dr. Ben Synth as he explores the cutting-edge science beyond Ozempic—triple-hormone agonists, oral alternatives, and breakthrough obesity treatments reshaping medicine. Discover the clinical trials and molecular innovations revolutionizing weight loss, moving from blockbuster drugs to next-generation therapies addressing obesity as the complex metabolic condition it is. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

What Comes After Ozempic? Next-Gen Weight Loss Drugs - Amycretin and the Amylin Revolution

Ben Synth explores amycretin, Novo Nordisk's experimental dual-agonist obesity drug combining GLP-1 and amylin pathways. Early trials showed 24% body weight loss in just 36 weeks—outpacing current treatments. The episode covers competing drugs, the overlooked role of amylin, and why targeting multiple hormonal systems may define obesity medicine's future. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

What Comes After Ozempic? Next-Gen Weight Loss Drugs - The Pill Race: End of the Needle

Ben Synth explores the race to develop oral weight loss pills that could match injectable drugs like Ozempic. Eli Lilly's orforglipron and competing candidates show 15-21% weight loss without needles or refrigeration—potentially transforming global access to obesity treatment. He examines the science, challenges, and implications of this pharmaceutical breakthrough for millions worldwide. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

What Comes After Ozempic? Next-Gen Weight Loss Drugs - The Triple Threat: Retatrutide

AI host Ben Synth explores retatrutide, Eli Lilly's groundbreaking triple-agonist obesity drug showing 24.2% weight loss in phase-two trials. Learn how this medication's unique mechanism targeting GLP-1, GIP, and glucagon receptors could deliver nearly 30% weight reduction, potentially revolutionizing metabolic disease treatment beyond what semaglutide achieved. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.